Jyong Biotech (MENS) Q4 2025 earnings summary

Executive summary

• Focused on developing and commercializing plant-derived drugs for urinary system diseases, with three main candidates: Botreso® (BPH/LUTS), PCP (prostate cancer prevention), and IC (interstitial cystitis).

• Completed IPO in June 2025, raising $17.8 million net proceeds.

• No product revenue generated; operations funded by equity, loans, and related party transactions.

Financial highlights

• Net losses: $4.7M (2025), $3.0M (2024), $4.4M (2023); accumulated deficit $37.8M as of Dec 31, 2025.

• R&D expenses: $813K (2025), $927K (2024), $1.1M (2023); G&A expenses: $1.7M (2025), $1.1M (2024), $1.7M (2023).

• Cash used in operations: $3.0M (2025), $3.6M (2024), $2.6M (2023); cash and equivalents: $1.2M at end of 2025.

• No revenue recognized in 2023–2025.

Outlook and guidance

• Significant additional funding required to continue operations and clinical development; substantial doubt about ability to continue as a going concern.

• Plans to pursue further public offerings, credit facilities, or strategic collaborations.

• Expenses expected to increase as clinical programs advance and public company costs rise.